PDS Biotechnology's Buy Rating Reiterated by HC Wainwright

On March 10, 2025, HC Wainwright reaffirmed its "Buy" rating for the shares of PDS Biotechnology (NASDAQ:PDSB), according to a report by Benzinga. The firm has set a target price of $21.00 for the stock.

Several other analysts have also recently addressed PDS Biotechnology in their reports. On November 25th, B. Riley lowered its price target for the company from $9.00 to $7.00 while maintaining a "buy" rating. StockNews.com, on the other hand, downgraded PDS from a “hold” to a “sell” rating in a report published on November 9th. Currently, one analyst has given the stock a sell rating, while three have issued buy ratings, and another has given it a strong buy rating. As per MarketBeat.com, the consensus rating for the company stands at “Moderate Buy” with a consensus target price of $11.67.

PDS Biotechnology Price Performance

As of Friday, shares of PDSB opened at $1.23. Over the past year, the stock has seen a low of $1.13 and a high of $6.00. The current market capitalization of PDS Biotechnology is approximately $46.98 million, with a price-to-earnings (PE) ratio of -1.06 and a beta of 1.68. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84, and a quick ratio of 2.84. In addition, PDSB's fifty-day moving average price is $1.49, while the 200-day moving average price is $2.34.

Institutional Inflows and Outflows

Recent data shows that a number of institutional investors have altered their stakes in PDS Biotechnology. For instance, Marshall Wace LLP increased its investment in the firm by 38.4% during the fourth quarter, acquiring a total of 39,024 shares now valued at approximately $64,000. Raymond James Financial Inc. also established a new position worth around $26,000 in the fourth quarter. Similarly, Jane Street Group LLC invested about $58,000 during the same period. Furthermore, Blair William & Co. IL raised its stake by 29.4%, now holding 157,500 shares worth about $257,000. Geode Capital Management LLC also increased its stake by 9.8%, holding 415,113 shares valued at $1,586,000 after a recent acquisition. Approximately 26.84% of the stock is held by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focusing on developing a pipeline of targeted cancer immunotherapies in the United States. One of its leading product candidates is PDS0101 (HPV16), which is currently undergoing Phase II clinical trials. This treatment aims to address recurrent and metastatic head and neck cancer, as well as human papillomavirus-associated malignancies.

PDSBiotechnology, Stocks, HCWainwright